Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, COR Collaborate In Product Discovery, Pharmacogenomics Deal

Premium

NEW HAVEN, Conn.--CuraGen recently announced a product discovery and pharmacogenomics agreement with COR Therapeutics. CuraGen said it will apply its SeqCalling, GeneCalling, and PathCalling technologies; related services; and pharmacogenomics expertise to identify new drug targets and develop new cardiovascular drugs.

CuraGen retains the rights to newly discovered protein therapeutics for use in the company's internal drug development programs, while COR retains the rights to small-molecule and inhibitory antibody therapeutics generated from the arrangement. The renewable collaboration is valued at about $2.6 million for an initial period of 18 months. CuraGen may also receive milestone and royalty payments for products developed by COR resulting from the cooperation.

CuraGen is "successfully applying" its genomics knowledge to assist collaborators in the pharmaceutical, agricultural, and biotechnology fields, said Jonathan Rothberg, chairman and CEO of CuraGen.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.